Premotor Parkinson's disease: Concepts and definitions

Movement Disorders

Volumn 27, Issue 5, 2012, Pages 608-616

  Siderowf, Andrew ^a   Lang, Anthony E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Early detection; Parkinson's disease; Sensitivity; Specificity

Indexed keywords

DOPAMINE TRANSPORTER; FLUORODEOXYGLUCOSE F 18; LEUCINE RICH REPEAT KINASE 2;

ANXIETY DISORDER; ARTICLE; CONSTIPATION; DEPRESSION; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE MARKER; DOPPLER ECHOGRAPHY; EARLY DIAGNOSIS; GENE MUTATION; GENETIC SCREENING; HEALTH CARE COST; HUMAN; NEUROPSYCHOLOGY; OLFACTORY NERVE DISEASE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATHOGENESIS; PATIENT SAFETY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREMOTOR PARKINSON DISEASE; PRIORITY JOURNAL; REM SLEEP; SCREENING; SENSITIVITY AND SPECIFICITY; SMELL TEST; THERAPY EFFECT;

EARLY DIAGNOSIS; HUMANS; MOTOR NEURONS; PARKINSON DISEASE;

EID: 84859813166     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24954     Document Type: Article

References (93)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55: 181-184.
2. Stern MB. The preclinical detection of Parkinson's disease: ready for prime time? Ann Neurol. 2004; 56: 169-171.
3. Siderowf A, Stern MB. Preclinical diagnosis of Parkinson's disease: are we there yet? Curr Neurol Neurosci Rep. 2006; 6: 295-301.
4. Louis ED, Bennett DA. Mild parkinsonian signs: an overview of an emerging concept. Mov Disord. 2007; 22: 1681-1688.
5. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001; 58: 1985-1992.
6. Muller A, Reichmann H, Livermore A, Hummel T. Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Trans. 2002; 109: 805-811.
7. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. 1988; 38: 1237-1244.
8. Haehner A, Boesveldt S, Berendse HW, et al. Prevalence of smell loss in Parkinson's disease. A multicenter study. Parkinsonism Relat Disord. 2009; 15: 490-494.
9. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol. 2008; 63: 167-173.
10. Abbott RD, Ross GW, White LR, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology. 2005; 65: 1442.
11. Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009; 72: 1296-1300.
12. Plazzi G, Cortelli P, Montagna P, et al. REM sleep behaviour disorder differentiates pure autonomic failure from multiple system atrophy with autonomic failure. J Neurol Neurosurg Psychiatry. 1998; 64: 683-685.
13. Iranzo A, Lomena F, Stockner H, et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 2011; 9: 1070-1077.
14. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology. 2001; 57: 456-462.
15. Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Arch Neurol. 2010; 67: 798-801.
16. Leentjens AFG, Van den Akker M, Metsemakers JFM, Lousberg R, Verhey FRJ. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord. 2003; 18: 414-418.
17. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord. 2000; 15: 669-677.
18. Gonera EG, vantHof M, Berger HJC, vanWeel C, Horstink WIM. Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord. 1997; 12: 871-876.
19. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc. 2004; 52: 784-748.
20. Menza MA, Mark MH, Burn DJ, Brooks DJ. Personality correlates of [18F]dopa striatal uptake: results of positron-emission tomography in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1995; 7: 176-179.
21. Glosser G, Clark C, Freundlich B, Kliner-Krenzel L, Flaherty P, Stern M. A controlled investigation of current and premorbid personality: characteristics of Parkinson's disease patients. Mov Disord. 1995; 10: 201-206.
22. Hubble JP, Venkatesh R, Hassanein RE, Gray C, Koller WC. Personality and depression in Parkinson's disease. J Nerv Ment Dis. 1993; 181: 657-662.
23. Arabia G, Grossardt BR, Colligan RC, et al. Novelty seeking and introversion do not predict the long-term risk of Parkinson disease. Neurology. 2010; 75: 349-357.
24. Adler CH, Connor DJ, Hentz JG, et al. Incidental Lewy body disease: Clinical comparison to a control cohort. Mov Disord. 2010; 25: 642-646.
25. Diederich NJ, Pieri V, Hipp G, Rufra O, Blyth S, Vaillant M. Discriminative power of different nonmotor signs in early Parkinson's disease. A case-control study. Mov Disord. 2010; 25: 882-887.
26. Marek KL, Seibyl JP, Zoghbi SS, et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996; 46: 231-237.
27. Holthoff VA, Vieregge P, Kessler J, et al. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol. 1994; 36: 176-182.
28. Piccini P, Burn DJ, Ceravolo R, et al. The role of inheritance in sporadic Parkinson's Disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 1999; 45: 577-582.
29. Braune S, Reinhardt M, Bathmann J, Krause T, Lehmann M, Lucking CH. Impaired cardiac uptake of meta-[123I]iodobenzylguanidine in Parkinson's disease with autonomic failure. Acta Neurol Scand. 1998; 97: 307-314.
30. Courbon F, Brefel-Courbon C, Thalamas C, et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord. 2003; 18: 890-897.
31. Braune S, Reinhardt M, Schnitzer R, Riedel A, Lucking CH. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy [see comment]. Neurology. 1999; 53: 1020-1025.
32. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci. 1998; 155: 60-67.
33. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography [see comment]. Neurology. 1995; 45: 182-184.
34. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol. 2001; 248: 684-689.
35. Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology. 2003; 60: 74-77.
36. Berg D, Roggendorf W, Schroder U, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol. 2002; 59: 999-1005.
37. Ruprecht-Dorfler P, Berg D, Tucha O, et al. Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease. Neuroimage. 2003; 18: 416-422.
38. Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology. 2011; 87: 848-856.
39. Kupsky WJ, Grimes MM, Sweeting J, Bertsch R, Cote LJ. Parkinson's disease and megacolon. Neurology. 1987; 37: 1253.
40. Beach TG, Adler CH, Lue LF, et al. Unified staging system for Lewy body disorders: Correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 2009; 117: 613-634.
41. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett. 2006; 396: 67-72.
42. Dickson D, Fujishiro H, DelleDonne A, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 2008; 115: 437-444.
43. Lebouvier T, Neunlist M, Bruley des Varannes S, et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One. 2010; 5: e12728.
44. Shannon KM, Keshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord. 2011 [Epub ahead of print].
45. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003; 24: 197-211.
46. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's Disease and mutations in the parkin gene. N Engl J Med. 2000; 342: 1560-1567.
47. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008; 7: 583-590.
48. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276: 2045-2047.
49. Ascherio A, Chen H, Weisskopf MG, et al. Pesticide exposure and risk for Parkinson's disease. Ann Neurol. 2006; 60: 187-203.
50. Abbott RD, Ross GW, White LR, et al. Midlife adiposity and the future risk of Parkinson's disease. Neurology. 2002; 59: 1051-1057.
51. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson's disease. JAMA. 2000; 283: 2674-2679.
52. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: False association or etiologic clue. Neurology. 1995; 45: 1041-1051.
53. Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69: 89-95.
54. El Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006; 20: 419-425.
55. Abdi F, Quinn JF, Jankovic J, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis. 2006; 9: 293-348.
56. Van Den Eeden SK, Tanner CM, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003; 157: 1015-1022.
57. Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep. 2002; 25: 120-138.
58. Stiasny-Kolster K, Doerr Y, Moller JC, et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain. 2005; 128: 126-137.
59. Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med. 2011; 12: 445-453.
60. Morens DM, Grandinetti A, Waslien CI, Park CB, Ross GW, White LR. Case-control study of idiopathic Parkinson's disease and dietary vitamin E intake. Neurology. 1996; 46: 1270-1274.
61. Thacker EL, O'Reilly EJ, Weisskopf MG, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology. 2007; 68: 764-768.
62. Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol. 2002; 155: 732-738.
63. Tanner CM, Goldman SM, Aston DA, et al. Smoking and Parkinson's disease in twins. Neurology. 2002; 58: 581-588.
64. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine Intake with risk of Parkinson's disease. JAMA. 2000; 283: 2674-2679.
65. Abbott RD, Ross GW, White LR, et al. Midlife adiposity and the future risk of Parkinson's disease. Neurology. 2002; 59: 1051-1057.
66. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease [see comment]. Neurology. 2001; 57: 456-462.
67. Ascherio A, Chen H, Weisskopf MG, et al. Pesticide exposure and risk for Parkinson's disease. Ann Neurol. 2006; 60: 187-203.
68. Hawkes C. Olfaction in neurodegenerative disorder. Mov Disord. 2003; 18: 364-372.
69. London B, Nabet B, Fisher AR, White B, Sammel MD, Doty RL. Predictors of prognosis in patients with olfactory disturbance. Ann Neurol. 2008; 63: 159-166.
70. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BLF, Wolters EC, Berendse HW. Idiopathic Hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol. 2004; 56: 173-181.
71. Jellinger K. Formation and development of Lewy pathology: a critical update. J Neurol. 2009; 256: 270-279.
72. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol. 2008; 115: 409-415.
73. Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG, on behalf of the MRC Cognitive Function ANS. Patterns and stages of alpha-synucleinopathy. Neurology. 2008; 70: 1042-1048.
74. de la Fuente-Fernández R, Schulzer M, Kuramoto L, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol. 2011; 69: 803-810.
75. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998; 64: 314-319.
76. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol. 2005; 62: 378-382.
77. Nurmi E, Ruottinen HM, Bergman J, et al. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord. 2001; 16: 608-615.
78. Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol. 1994; 36: 759-764.
79. Berendse HW, Ponsen MM. Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging. Parkinsonism Relat Disord. 2009; 15( Suppl 3): S26-S30.
80. Piccini P, Morrish PK, Turjanski N, et al. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol. 1997; 41: 222-229.
81. Marras C, Goldman S, Smith A, et al. Smell identification ability in twin pairs discordant for Parkinson's disease. Mov Disord. 1920; 6: 687-693.
82. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BLF, Wolters EC, Berendse HW. Idiopathic Hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol. 2004; 56: 173-181.
83. Haehner A, Hummel T, Reichmann H. Olfactory dysfunction as a diagnostic marker for Parkinson's disease. Expert Rev Neurother. 2009; 9: 1773-1779.
84. Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology. 2010; 75: 494-499.
85. Guidelines for the molecular genetics predictive test in Huntington's disease. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington's Chorea. Neurology. 1994; 44: 1533-1536.
86. Kessler S, Field T, Worth L, Mosbarger H. Attitudes of persons at risk for Huntington disease toward predictive testing. Am J Med Genet. 1987; 26: 259-270.
87. Markel DS, Young AB, Penney JB. At-risk persons' attitudes toward presymptomatic and prenatal testing of Huntington disease in Michigan. Am J Med Genet. 1987; 26: 295-305.
88. Mastromauro C, MYERS RH, Berkman B. Attitudes toward presymptomatic testing in Huntington disease. Am J Med Genet. 1987; 26: 271-282.
89. Babul R, Adam S, Kremer B, et al. Attitudes toward direct predictive testing for the Huntington disease gene-relevance for other adult-onset disorders. JAMA. 1993; 270: 2321-2325.
90. Quaid KA, Morris M. Reluctance to undergo predictive testing - the case of Huntington disease. Am J Med Genet. 1993; 45: 41-45.
91. Dahodwala N, Connolly J, Farmer J, Stern MB, Jennings D, Siderowf A. Interest in predictive testing for Parkinson's disease: impact of neuroprotective therapy. Parkinsonism Relat Disord. 2007; 13: 495-499.
92. Van Den Eeden SK, Tanner CM, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003; 157: 1015-1022.
93. Marder K, Tang MX, Mejia H, et al. Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology. 1996; 47: 155-160.